ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/Pharmaceutical Intermediate/Buserelin EP Impurity C
C49H74N12O10
991.2 g/mol
Pharmaceutical Intermediate

Buserelin EP Impurity C

CAS70280-55-6
Category
Pharmaceutical Intermediate
Compound Class
Peptide
Primary Use
Pharmaceutical Intermediate

Buserelin EP Impurity C is a peptide-related compound used as a reference standard for quality control in the manufacturing of the pharmaceutical intermediate buserelin. It serves as a characterized impurity to ensure the purity and consistency of buserelin batches during production.

Reference standard for buserelin impurity testingQuality control in pharmaceutical intermediate manufacturing

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing Buserelin EP Impurity C?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

ReferenceSame Category

5-Bromo-2-(trifluoromethyl)aniline

CAS703-91-3

pharmaceutical intermediate

ReferenceSame Category

Potassium N-(acetoacetyl)sulfanilate

CAS70321-85-6

pharmaceutical intermediate

ReferenceSame Category

4-Hydroxymethylthiazole

CAS7036-04-6

pharmaceutical intermediate

ReferenceSame Category

Ethyl 2-(5,6-dichloro-2-imino-1,2-dihydroquinazolin-3(4H )-yl)acetate hydrobromide

CAS70381-75-8

pharmaceutical intermediate

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more
Identifiers
IUPAC Name

(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2-methylpropan-2-yl)oxy]propanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-ethylpyrrolidine-2-carboxamide

InChIKey

BAVFTTUHVOJIOZ-RKWGXVJDSA-N

SMILES

CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N

Synonyms (5)
  • Buserelin EP Impurity C
  • BUSERELIN IMPURITY C
  • Buserelin-(3-9)-peptide,

Sourcing Buserelin EP Impurity C?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→